Aug 09, 2023 7:05am EDT Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgia
Aug 03, 2023 4:05pm EDT Virios Therapeutics to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
Jul 17, 2023 7:05am EDT Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study
May 25, 2023 4:05pm EDT Virios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
May 15, 2023 7:05am EDT Virios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat Fibromyalgia
May 04, 2023 7:05am EDT Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
Apr 24, 2023 4:15pm EDT Virios Therapeutics Announces Initial FDA Feedback on Proposed IMC-1 Phase 3 Program for Treatment of Fibromyalgia
Mar 14, 2023 7:05am EDT Virios Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results
Mar 07, 2023 7:05am EST Virios Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14, 2023
